Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.
YunYu LinYan LeiLinWei LiXiaoxing SuQiqi TianJiayan WuPublished in: OncoTargets and therapy (2022)
fusion in clinical personalized treatment. The good response to crizotinib therapy emphasizes the importance of DNA-based and RNA-based NGS in rare fusion identification in clinical practice.